Your browser doesn't support javascript.
loading
The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.
Ouellet, Véronique; Aprikian, Armen; Bergeron, Alain; Brimo, Fadi; Bristow, Robert G; Chevalier, Simone; Drachenberg, Darrel; Fazli, Ladan; Fleshner, Neil E; Gleave, Martin; Karakiewicz, Pierre; Klotz, Laurence; Lacombe, Louis; Lattouf, Jean-Baptiste; van der Kwast, Theodorus; Squire, Jeremy A; Latour, Mathieu; Trudel, Dominique; Mes-Masson, Anne-Marie; Saad, Fred.
Afiliación
  • Ouellet V; Institut du cancer de Montréal and Centre de recherche du Centre hospitalier de l'Université de Montréal, 900, St-Denis St, room R10-464, Montréal, Québec, H2X 0A9, Canada.
  • Aprikian A; Research Institute of McGill University Health Center and Department of Surgery (Urology), McGill University, Montréal, Québec, Canada.
  • Bergeron A; CHU de Québec-Université Laval and Department of Surgery, Université Laval, Québec City, Québec, Canada.
  • Brimo F; Department of Pathology, McGill University Health Centre, Montréal, Québec, Canada.
  • Bristow RG; Department of Medical Biophysics and Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
  • Chevalier S; University Health Network, Toronto, ON, Canada.
  • Drachenberg D; Research Institute of McGill University Health Center and Department of Surgery (Urology), McGill University, Montréal, Québec, Canada.
  • Fazli L; University of Manitoba and Manitoba Prostate Centre, Winnipeg, MB, Canada.
  • Fleshner NE; Vancouver Prostate Centre, Vancouver, BC, Canada.
  • Gleave M; University Health Network, Toronto, ON, Canada.
  • Karakiewicz P; Division of Urology, Department of Surgery of University Health Network, University of Toronto, Toronto, ON, Canada.
  • Klotz L; Vancouver Prostate Centre, Vancouver, BC, Canada.
  • Lacombe L; Department of Urologic Sciences, Vancouver, BC, Canada.
  • Lattouf JB; Cancer Prognostics and Health Outcomes Unit, Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
  • van der Kwast T; Department of Surgery, Université de Montréal, Montréal, Québec, Canada.
  • Squire JA; Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Latour M; CHU de Québec-Université Laval and Department of Surgery, Université Laval, Québec City, Québec, Canada.
  • Trudel D; Institut du cancer de Montréal and Centre de recherche du Centre hospitalier de l'Université de Montréal, 900, St-Denis St, room R10-464, Montréal, Québec, H2X 0A9, Canada.
  • Mes-Masson AM; Department of Surgery, Université de Montréal, Montréal, Québec, Canada.
  • Saad F; University Health Network, Toronto, ON, Canada.
BMC Urol ; 18(1): 78, 2018 Sep 10.
Article en En | MEDLINE | ID: mdl-30200929
ABSTRACT

BACKGROUND:

Refinement of parameters defining prostate cancer (PC) prognosis are urgently needed to identify patients with indolent versus aggressive disease. The Canadian Prostate Cancer Biomaker Network (CPCBN) consists of researchers from four Canadian provinces to create a validation cohort to address issues dealing with PC diagnosis and management.

METHODS:

A total of 1512 radical prostatectomy (RP) specimens from five different biorepositories affiliated with teaching hospitals were selected to constitute the cohort. Tumoral and adjacent benign tissues were arrayed on tissue microarrays (TMAs). A patient clinical database was developed and includes data on diagnosis, treatment and clinical outcome.

RESULTS:

Mean age at diagnosis of patients in the cohort was 61 years. Of these patients, 31% had a low grade (≤6) Gleason score (GS), 55% had GS 7 (40% of 3 + 4 and 15% of 4 + 3) and 14% had high GS (≥8) PC. The median follow-up of the cohort was 113 months. A total of 34% had a biochemical relapse, 4% developed bone metastasis and 3% of patients died from PC while 9% died of other causes. Pathological review of the TMAs confirmed the presence of tumor and benign tissue cores for > 94% of patients. Immunohistochemistry and FISH analyses, performed on a small set of specimens, showed high quality results and no biorepository-specific bias.

CONCLUSIONS:

The CPCBN RP cohort is representative of real world PC disease observed in the Canadian population. The frequency of biochemical relapse and bone metastasis as events allows for a precise assessment of the prognostic value of biomarkers. This resource is available, in a step-wise manner, for researchers who intend to validate prognostic biomarkers in PC. Combining multiple biomarkers with clinical and pathologic parameters that are predictive of outcome will aid in clinical decision-making for patients treated for PC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Próstata / Neoplasias de la Próstata / Biomarcadores de Tumor Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: BMC Urol Asunto de la revista: UROLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Próstata / Neoplasias de la Próstata / Biomarcadores de Tumor Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: BMC Urol Asunto de la revista: UROLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Canadá